Dr. Tom Chittenden is a globally recognized polymath at the intersection of artificial intelligence, quantum computing, and the life sciences. Currently serving as the Chief Technology Officer at ProFound Therapeutics, he leads the development of the System for Agentic Graph Exploration (SAGE), a multi-agent causal AI platform designed to navigate the "causal logic of biology" and discover novel drug targets. His career is characterized by the application of "Manhattan Project" style R&D intensity to the most complex challenges in human health, earning him a place in the Global Genius Directory as one of the world's top minds.

With a dual doctoral background, a PhD in Molecular Cell Biology from Virginia Tech and a DPhil in Statistics from the University of Oxford, Dr. Chittenden possesses a unique ability to synthesize high-dimensional multi-omics data with advanced computational frameworks. He has held chief scientific and technology roles at several pioneering firms, including Genuity Science, HiberCell, and BullFrog AI, where he successfully deployed industry-first integrated quantum machine learning and causal AI strategies. His leadership has directly resulted in tens of millions of dollars in industry contracts and high-impact publications in journals such as Science, Nature Metabolism, and the Journal of Clinical Investigation.

Beyond his corporate leadership, Dr. Chittenden is a dedicated educator and researcher, serving as an Honorary Professor at Queen Mary University of London and having taught for nearly a decade at Harvard Medical School and MIT. His professional foundation is exceptionally diverse, beginning with service as a Corporal of the Guard in the U.S. Marine Corps before transitioning into clinical cardiology and ultimately becoming a leader in the "Bio-AI" revolution. As the Chairman of the Complex Biological Systems Alliance, he continues to foster global scientific discourse aimed at eradicating disease through the synergy of human intellect and machine intelligence.